Hot Features
Premium
Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 35,795 |
|
|||||
| News | - | ||||||
| Day High | 4.89 | Low High |
|||||
| Day Low | 4.62 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Affimed NV | AFMD | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.0855 | -1.75% | 4.7945 | 09:46:35 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.88 | 4.62 | 4.89 | 4.88 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 231 | 35,795 | US$ 4.76 | US$ 170,447 | - | 2.235 - 11.10 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 09:44:17 | 2 | US$ 4.7999 | USD |
Affimed NV Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 71.09M | 14.93M | - | 12.97M | -105.94M | -7.09 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Affimed NV News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AFMD Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.29 | 5.46 | 4.62 | 5.05 | 67,342 | -0.4955 | -9.37% |
| 1 Month | 5.33 | 7.24 | 4.62 | 6.03 | 108,506 | -0.5355 | -10.05% |
| 3 Months | 5.60 | 7.24 | 4.245 | 5.83 | 399,361 | -0.8055 | -14.38% |
| 6 Months | 3.55 | 7.40 | 2.235 | 5.00 | 763,073 | 1.24 | 35.06% |
| 1 Year | 8.165 | 11.10 | 2.235 | 5.77 | 773,838 | -3.37 | -41.28% |
| 3 Years | 112.80 | 117.40 | 2.235 | 34.53 | 1,210,709 | -108.01 | -95.75% |
| 5 Years | 33.40 | 117.40 | 2.235 | 42.14 | 1,244,185 | -28.61 | -85.65% |
Affimed NV Description
| Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany. |
